HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $32,870 | -24.0% | 860,474 | -28.2% | 0.04% | -15.1% |
Q2 2023 | $43,235 | +61.8% | 1,198,667 | +71.3% | 0.05% | +51.4% |
Q1 2023 | $26,717 | +5.4% | 699,604 | +57.0% | 0.04% | 0.0% |
Q4 2022 | $25,351 | -99.9% | 445,541 | -8.6% | 0.04% | +25.0% |
Q3 2022 | $19,273,000 | +7200.4% | 487,443 | +8020.0% | 0.03% | – |
Q2 2022 | $264,000 | +3671.4% | 6,003 | +3010.4% | 0.00% | – |
Q1 2022 | $7,000 | -94.5% | 193 | -93.9% | 0.00% | – |
Q4 2021 | $127,000 | +23.3% | 3,177 | +25.2% | 0.00% | – |
Q3 2021 | $103,000 | -15.6% | 2,538 | -6.0% | 0.00% | – |
Q2 2021 | $122,000 | +17.3% | 2,700 | +7.9% | 0.00% | – |
Q1 2021 | $104,000 | +20.9% | 2,502 | +23.7% | 0.00% | – |
Q4 2020 | $86,000 | +62.3% | 2,022 | 0.0% | 0.00% | – |
Q3 2020 | $53,000 | -98.7% | 2,022 | -98.7% | 0.00% | -100.0% |
Q2 2020 | $4,041,000 | +9084.1% | 150,740 | +5877.0% | 0.01% | – |
Q4 2019 | $44,000 | +528.6% | 2,522 | +443.5% | 0.00% | – |
Q3 2019 | $7,000 | – | 464 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |